This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): ATOCK, (R,R)-Formoterol, Arformoterol tartrate
Description: Brovana is a single isomer form of the beta(2)-adrenoceptor agonist formoterol. It is being developed as a nebulized preparation for the treatment of respiratory disorders.
Deal Structure: Brovana was originally developed by Sepracor.
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.
Pink Sheet Sepracor COPD Treatment Approved
Additional information available to subscribers only: